Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression: predictive factors of response to antirejection therapy

Abstract

Response to antirejection treatment in ACR in liver transplantation can be predicted by several clinical and laboratory data. ACR episodes with factors predictive of therapeutic unresponsiveness could benefit from more aggressive antirejection treatment.

Anti-thymocyte Globulin for the Treatment of Acute Cellular Rejection Following Liver Transplantation

“…However, with each approach, some patients will still develop acute rejection. Up to one-third of LT recipients develop SRR and require treatment with depleting antibodies [1,7]. Increased utilization of extended criteria donor allografts for increasingly decompensated patients also magnifies the infectious risk for these induction agents.…”

“…Acute cellular rejection (ACR) used to be a common complication affecting up to 70% of recipients within the first year, although rejection rates after LT are lower than after most other solid-organ transplants [1,2]. ACR usually occurs during the first few weeks post-LT.…”

“…Established risk factors for ACR include African-American race, autoimmune liver disease, fulminant hepatic failure, and ABO incompatible grafts [1,[5][6][7][8][9][10][11][12]. Other factors that have been associated with ACR are CMV infection, HLA mismatch, and significant reperfusion injury; however, these factors may not be as important when using modern immunosuppressive regimens.…”

Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients

“…Typical rejection management involves optimization of baseline immunosuppression and methylprednisolone boluses. However, 28-35% of patients do not respond to high-dose steroid therapy and require further treatment [1][2][3][4][5].…”

A Comparison of Outcomes Between OKT3 and Antithymocyte Globulin for Treatment of Steroid-Resistant Rejection in Hepatitis C Liver Transplant Recipients

“…Acute cellular rejection (ACR) used to be a common complication affecting up to 70% of liver recipients within the first year, although rejection rates are lower than after most other solid-organ transplants (5,6). The discovery of new antirejection medications, most importantly the first calcineurin inhibitor cyclosporine A, resulted in a significant reduction in rejection rates over the past two decades (7).…”